Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab To Present Data From Phase 1 Trial Of ZL-1310, For DLL3+ Solid Tumors

Oct 9 (Reuters) - Zai Lab Ltd  9688.HK :
    * ZAI LAB TO PRESENT DATA FROM PHASE 1 TRIAL OF ZL-1310, ITS
INVESTIGATIONAL ANTIBODY-DRUG CONJUGATE (ADC) FOR DLL3+ SOLID
TUMORS, AT EORTC-NCI-AACR SYMPOSIUM (ENA) 2024
    * ZAI LAB LTD - TO PRESENT PHASE 1 DATA OF ZL-1310 AT ENA
2024

Source text for Eikon:  ID:nBw1DpNT9a 
Further company coverage:  9688.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news